18F-Labeled Biomolecules Residualizing Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for radiolabeling biomolecules, such as monoclonal antibodies and peptides, face challenges in retaining radioactivity within tumor cells due to rapid internalization and degradation, leading to low retention of radioactivity for effective imaging or treatment of cancer.
Innovation Solution
The development of methods and compounds for radiolabeling biomolecules with 18F using prosthetic agents like 6-[18F]fluoronicotinyl-PEG4-methyltetrazine and 6-[18F]fluoronicotinyl-PEG4-GK-TCO, employing inverse electron-demand Diels-Alder cycloaddition reactions and click chemistry, to create 18F-labeled biomolecules that minimize dehalogenation and maximize retention in cancer cells while preserving biological activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If biomolecules are labeled with radionuclides for tumor detection, then imaging capability is improved, but radioactivity retention in tumor cells deteriorates due to rapid internalization and degradation
Solution Approach 1:
The patent introduces residualizing agents as intermediary compounds that mediate between the radionuclide label and the biomolecule. These agents contain functional groups that form stable complexes with degradation products, preventing radioactivity washout. For example, the residualizing agent contains a residualizing functional group that binds to catabolites of the biomolecule, trapping radioactivity within the cell while allowing the biomolecule to perform its imaging function.
Solution Approach 2:
The patent creates composite structures by combining radionuclides, biomolecules, and residualizing agents into integrated labeling complexes. The composite labeling compound comprises multiple functional components: the radionuclide for imaging, the biomolecule for target recognition, and the residualizing agent for radioactivity retention. This composite approach allows simultaneous achievement of imaging capability and radioactivity retention.
2Reliability
If residualizing agents are used to trap radioactivity, then radioactivity retention is improved, but dehalogenation loss worsens
Solution Approach 1:
The patent modifies chemical parameters of the labeling compound by selecting specific radionuclides with appropriate half-lives and decay modes, and by choosing residualizing agents with optimal chemical stability. For instance, using fluorine-18 with its 110-minute half-life and positron emission properties, combined with residualizing agents that form stable fluorine-containing complexes, reduces dehalogenation while maintaining retention.
Solution Approach 2:
The patent converts the potentially harmful degradation process into a beneficial retention mechanism. Instead of preventing degradation, the residualizing agent is designed to specifically capture degradation products, transforming the harmful washout effect into a beneficial trapping mechanism. The degradation products, which would normally cause radioactivity loss, are now harnessed to deliver and retain radioactivity in the target tissue.
3Measurement precision
If biomolecules are internalized into tumor cells, then targeting specificity is improved, but radioactivity retention deteriorates due to rapid degradation and washout
Solution Approach 1:
The patent applies preliminary action by pre-attaching the residualizing agent to the biomolecule before administration. This ensures that the retention mechanism is already in place before the biomolecule enters the cell and degrades. The residualizing agent is incorporated into the biomolecule structure in advance, so when degradation occurs inside the cell, the radioactivity is immediately trapped by the pre-positioned residualizing functional group.
Solution Approach 2:
The residualizing agent acts as an intermediary that bridges the gap between cell internalization and radioactivity retention. It is positioned between the radionuclide and the cellular degradation machinery, capturing degradation intermediates and preventing their exit from the cell. This intermediary function allows the biomolecule to be internalized for specific targeting while the residualizing agent ensures subsequent radioactivity retention.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These methods result in higher tumor retention of radioactivity and reduced normal tissue uptake, enabling effective imaging and potential therapeutic applications for cancer diagnosis and treatment.
Implementation Method 1
reacting the functionalized biomolecule and the 18F-containing reagent via an inverse electron-demand Diels-Alder cycloaddition reaction to provide the 18F-labeled biomolecule
Implementation Method 2
reacting the first and second compounds via click chemistry to give the 18F-labeled residualizing agent
Implementation Method 3
reacting the boronate precursor with 18F-fluoride to provide the 18F-labeled residualizing agent
Data Source
AI summary
The application is drawn to 18F-radiolabeled residualizing agents and biomolecules and methods for radiolabeling biomolecules with radioactive fluorine atoms. The biomolecules have an affinity for particular types of cells and may specifically bind a certain cell, such as a cancer cell. Relevant biomolecules include antibodies, monoclonal antibodies, antibody fragments, peptides, other proteins, nanoparticles and aptamers. The application further provides compositions including such labeled biomolecules, as well as methods of using the labeled biomolecules and/or compositions in imaging applications.